Molecular pathways in non-alcoholic fatty liver disease

References

• AnguloPObesity and nonalcoholic fatty liver diseaseNutr Rev2007656 Pt 25763
   PubMed Web of Science ®Google Scholar
• LazoMClarkJMThe epidemiology of nonalcoholic fatty liver disease: a global perspectiveSemin Liver Dis200828433935018956290
   PubMed Web of Science ®Google Scholar
• WilliamsCDStengelJAsikeMIPrevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective studyGastroenterology2011140112413120858492
   PubMed Web of Science ®Google Scholar
• NakamutaMKohjimaMMorizonoSEvaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver diseaseInt J Mol Med200516463163516142397
   PubMed Web of Science ®Google Scholar
• MachadoMMarques-VidalPCortez-PintoHHepatic histology in obese patients undergoing bariatric surgeryJ Hepatol200645460060616899321
   PubMed Web of Science ®Google Scholar
• WieckowskaAPapouchadoBGLiZLopezRZeinNNFeldsteinAEIncreased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitisAm J Gastroenterol200810361372137918510618
   PubMed Web of Science ®Google Scholar
• EkstedtMFranzénLEMathiesenULLong-Term Follow-up of Patients with NAFLD and Elevated Liver EnzymesHepatology200644486587317006923
   PubMed Web of Science ®Google Scholar
• FarrellGCLarterCZNonalcoholic fatty liver disease: from steatosis to cirrhosisHepatology2006432 Suppl 1S99S11216447287
   PubMed Web of Science ®Google Scholar
• DowmanJKTomlinsonJWNewsomePNSystematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitisAliment Pharmacol Ther201133552554021198708
   PubMed Web of Science ®Google Scholar
• MarchesiniGBugianesiEForlaniGNonalcoholic fatty liver, steatohepatitis, and the metabolic syndromeHepatology200337491792312668987
   PubMed Web of Science ®Google Scholar
• AdamsLAWatersORKnuimanMWElliottRROlynykJKNAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up studyAm J Gastroenterol2009104486186719293782
   PubMed Web of Science ®Google Scholar
• AdamsLAFeldsteinAENon-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitisJ Dig Dis2011121101621091933
   PubMed Web of Science ®Google Scholar
• YanEDurazoFTongMHongKNonalcoholic fatty liver disease: pathogenesis, identification, progression, and managementNutr Rev2007658 Pt 137638417867371
   PubMed Web of Science ®Google Scholar
• SorbiDBoyntonJLindorKDThe ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver diseaseAm J Gastroenterol19999441018102210201476
   PubMed Web of Science ®Google Scholar
• AdamsLAAnguloPLindorKDNonalcoholic fatty liver diseaseCMAJ2005172789990515795412
   PubMed Web of Science ®Google Scholar
• FestiDSchiumeriniRMarziLReview article: the diagnosis of non-alcoholic fatty liver disease – availability and accuracy of non-invasive methodsAliment Pharmacol Ther201337439240023278163
   PubMed Web of Science ®Google Scholar
• FedericoATrappoliereMLoguercioCTreatment of patients with non-alcoholic fatty liver disease: current views and perspectivesDig Liver Dis2006381178980116750661
   PubMedGoogle Scholar
• PacificoLCelestreMAnaniaCPaolantonioPChiesaCLaghiAMRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver diseaseActa Paediatr200796454254717306008
   PubMed Web of Science ®Google Scholar
• LewisJRMohantySRNonalcoholic fatty liver disease: a review and updateDig Dis Sci201055356057820101463
   PubMed Web of Science ®Google Scholar
• YilmazYUlukayaEDolarEA “biomarker biopsy” for the diagnosis of NASH: promises from CK-18 fragmentsObes Surg2008181115071508 author reply 1509–151018679759
   PubMed Web of Science ®Google Scholar
• SchwengerKJAllardJPClinical approaches to non-alcoholic fatty liver diseaseWorld J Gastroenterol20142071712172324587650
   PubMed Web of Science ®Google Scholar
• McCarthyEMRinellaMEThe role of diet and nutrient composition in nonalcoholic fatty liver diseaseJ Acad Nutr Diet2012112340140922717200
   PubMed Web of Science ®Google Scholar
• PromratKKleinerDENiemeierHMRandomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitisHepatology201051112112919827166
   PubMed Web of Science ®Google Scholar
• St GeorgeABaumanAJohnstonAFarrellGCheyTGeorgeJEffect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factorsJ Gastroenterol Hepatol200924339940719067776
   PubMed Web of Science ®Google Scholar
• HaukelandJWKonopskiZEggesbøHBMetformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trialScand J Gastroenterol200944785386019811343
   PubMed Web of Science ®Google Scholar
• OhMKWinnJPoordadFReview article: diagnosis and treatment of non-alcoholic fatty liver diseaseAliment Pharmacol Ther200828550352218532991
   PubMed Web of Science ®Google Scholar
• Van WagnerLBRinellaMEThe role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitisTherap Adv Gastroenterol201144249263
   Google Scholar
• LutchmanGModiAKleinerDEThe effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitisHepatology200746242442917559148
   PubMed Web of Science ®Google Scholar
• AithalGPThomasJAKayePVRandomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitisGastroenterology200813541176118418718471
   PubMed Web of Science ®Google Scholar
• MaroniLGuastiLCastiglioniLLipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver diseaseAm J Med Sci2011342538338721629037
   PubMed Web of Science ®Google Scholar
• EkstedtMFranzénLEMathiesenULHolmqvistMBodemarGKechagiasSStatins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up studyJ Hepatol200747113514117400325
   PubMed Web of Science ®Google Scholar
• TandraSVuppalanchiRUse of statins in patients with liver diseaseCurr Treat Options Cardiovasc Med200911427227819627660
   PubMedGoogle Scholar
• ChalasaniNYounossiZLavineJEThe diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological AssociationHepatology20125562005202322488764
   PubMed Web of Science ®Google Scholar
• MussoGGambinoRCassaderMRecent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)Prog Lipid Res200948112618824034
   PubMed Web of Science ®Google Scholar
• PettaSMuratoreCCraxìANon-alcoholic fatty liver disease pathogenesis: the present and the futureDig Liver Dis200941961562519223251
   PubMedGoogle Scholar
• UtzschneiderKMKahnSEReview: the role of insulin resistance in nonalcoholic fatty liver diseaseJ Clin Endocrinol Metab200691124753476116968800
   PubMed Web of Science ®Google Scholar
• HotamisligilGSInflammation and metabolic disordersNature2006444712186086717167474
   PubMed Web of Science ®Google Scholar
• SavageDBSempleRKRecent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistanceCurr Opin Lipidol201021432933620581678
   PubMed Web of Science ®Google Scholar
• PosticCGirardJContribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered miceJ Clin Invest2008118382983818317565
   PubMed Web of Science ®Google Scholar
• LewisGFCarpentierAAdeliKGiaccaADisordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetesEndocr Rev200223220122911943743
   PubMed Web of Science ®Google Scholar
• TilgHMoschenAREvolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesisHepatology20105251836184621038418
   PubMed Web of Science ®Google Scholar
• KoliwadSKStreeperRSMonettiMDGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammationJ Clin Invest2010120375676720124729
   PubMed Web of Science ®Google Scholar
• YamaguchiKYangLMcCallSInhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitisHepatology20074561366137417476695
   PubMed Web of Science ®Google Scholar
• AmaroAFabbriniEKarsMDissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemiaGastroenterology2010139114915320303351
   PubMed Web of Science ®Google Scholar
• FeldsteinAEWerneburgNWCanbayAFree fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathwayHepatology200440118519415239102
   PubMed Web of Science ®Google Scholar
• MaríMCaballeroFColellAMitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitisCell Metab20064318519816950136
   PubMed Web of Science ®Google Scholar
• CheungOSanyalAJAbnormalities of lipid metabolism in nonalcoholic fatty liver diseaseSemin Liver Dis200828435135918956291
   PubMed Web of Science ®Google Scholar
• MalhiHGoresGJMolecular mechanisms of lipotoxicity in nonalcoholic fatty liver diseaseSemin Liver Dis200828436036918956292
   PubMed Web of Science ®Google Scholar
• ArnerPHuman fat cell lipolysis: biochemistry, regulation and clinical roleBest Pract Res Clin Endocrinol Metab200519447148216311212
   PubMed Web of Science ®Google Scholar
• DelarueJMagnanCFree fatty acids and insulin resistanceCurr Opin Clin Nutr Metab Care200710214214817285001
   PubMed Web of Science ®Google Scholar
• BerkPDRegulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndromeHepatology20084851362137618972439
   PubMed Web of Science ®Google Scholar
• MartinGNemotoMGelmanLThe human fatty acid transport protein-1 (SLC27A1; FATP-1) cDNA and gene: organization, chromosomal localization, and expressionGenomics200066329630410873384
   PubMed Web of Science ®Google Scholar
• GeFZhouSHuCLobdellHBerkPDInsulin- and leptin-regulated fatty acid uptake plays a key causal role in hepatic steatosis in mice with intact leptin signaling but not in ob/ob or db/db miceAm J Physiol Gastrointest Liver Physiol20102994G855G86620595619
   PubMed Web of Science ®Google Scholar
• ZhouSLStumpDSorrentinoDPotterBJBerkPDAdipocyte differentiation of 3T3-L1 cells involves augmented expression of a 43-kDa plasma membrane fatty acid-binding proteinJ Biol Chem19922672014456144611629231
   PubMed Web of Science ®Google Scholar
• ZhouSLStumpDKiangCLIsolaLMBerkPDMitochondrial aspartate aminotransferase expressed on the surface of 3T3-L1 adipocytes mediates saturable fatty acid uptakeProc Soc Exp Biol Med199520832632707878064
   PubMed Web of Science ®Google Scholar
• TrigattiBLAndersonRGGerberGEIdentification of caveolin-1 as a fatty acid binding proteinBiochem Biophys Res Commun19992551343910082651
   PubMed Web of Science ®Google Scholar
• DoegeHStahlAProtein-mediated fatty acid uptake: novel insights from in vivo modelsPhysiology (Bethesda)20062125926816868315
   PubMed Web of Science ®Google Scholar
• DoegeHBaillieRAOrtegonAMTargeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasisGastroenterology200613041245125816618416
   PubMed Web of Science ®Google Scholar
• AuingerAValentiLPfeufferMA promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosisHorm Metab Res2010421285484920945272
   PubMed Web of Science ®Google Scholar
• FernándezMAAlborCIngelmo-TorresMCaveolin-1 is essential for liver regenerationScience200631357931628163216973879
   PubMed Web of Science ®Google Scholar
• MastrodonatoMCalamitaGRossiRAltered distribution of caveolin-1 in early liver steatosisEur J Clin Invest201141664265121250982
   PubMed Web of Science ®Google Scholar
• Miquilena-ColinaMELima-CabelloESánchez-CamposSHepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis CGut201160101394140221270117
   PubMed Web of Science ®Google Scholar
• InoueMOhtakeTMotomuraWIncreased expression of PPARgamma in high fat diet-induced liver steatosis in miceBiochem Biophys Res Commun2005336121522216125673
   PubMed Web of Science ®Google Scholar
• BuquéXMartínezMJCanoAA subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker ratsJ Lipid Res201051350051319783528
   PubMed Web of Science ®Google Scholar
• DegracePMoindrotBMohamedIUpregulation of liver VLDL receptor and FAT/CD36 expression in LDLR−/− apoB100/100 mice fed trans-10, cis-12 conjugated linoleic acidJ Lipid Res200647122647265516957181
   PubMed Web of Science ®Google Scholar
• ZhouJFebbraioMWadaTHepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosisGastroenterology2008134255656718242221
   PubMed Web of Science ®Google Scholar
• GrecoDKotronenAWesterbackaJGene expression in human NAFLDAm J Physiol Gastrointest Liver Physiol20082945G1281G128718388185
   PubMed Web of Science ®Google Scholar
• BechmannLPGieselerRKSowaJ-PApoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitisLiver Int201030685085920408954
   PubMed Web of Science ®Google Scholar
• FuruhashiMHotamisligilGSFatty acid-binding proteins: role in metabolic diseases and potential as drug targetsNat Rev Drug Discov20087648950318511927
   PubMed Web of Science ®Google Scholar
• KarakasSEAlmarioRUKimKSerum fatty acid binding protein 4, free fatty acids, and metabolic risk markersMetabolism20095871002100719394980
   PubMed Web of Science ®Google Scholar
• ZimmermanAWVeerkampJHNew insights into the structure and function of fatty acid-binding proteinsCell Mol Life Sci20025971096111612222958
   PubMed Web of Science ®Google Scholar
• ChmurzyńskaAThe multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphismJ Appl Genet2006471394816424607
   PubMed Web of Science ®Google Scholar
• KrusinováEPelikánováTFatty acid binding proteins in adipose tissue: a promising link between metabolic syndrome and atherosclerosis?Diabetes Res Clin Pract200882Suppl 2S127S13418977052
   PubMed Web of Science ®Google Scholar
• TaskinenMRAdielsMWesterbackaJDual metabolic defects are required to produce hypertriglyceridemia in obese subjectsArterioscler Thromb Vasc Biol20113192144215021778423
   PubMed Web of Science ®Google Scholar
• WesterbackaJKolakMKiviluotoTGenes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjectsDiabetes200756112759276517704301
   PubMed Web of Science ®Google Scholar
• FalconADoegeHFluittAFATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetaseAm J Physiol Endocrinol Metab20102993E384E39320530735
   PubMed Web of Science ®Google Scholar
• DoegeHGrimmDFalconASilencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemiaJ Biol Chem200828332221862219218524776
   PubMed Web of Science ®Google Scholar
• NieBParkHMKazantzisMSpecific bile acids inhibit hepatic fatty acid uptake in miceHepatology20125641300131022531947
   PubMed Web of Science ®Google Scholar
• OkamuraMInagakiTTanakaTSakaiJRole of histone methylation and demethylation in adipogenesis and obesityOrganogenesis201061243220592862
   PubMed Web of Science ®Google Scholar
• SanyalAJChalasaniNKowdleyKVPioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitisN Engl J Med2010362181675168520427778
   PubMed Web of Science ®Google Scholar
• FabbriniESullivanSKleinSObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implicationsHepatology201051267968920041406
   PubMed Web of Science ®Google Scholar
• BechmannLPHannivoortRAGerkenGHotamisligilGSTraunerMCanbayAThe interaction of hepatic lipid and glucose metabolism in liver diseasesJ Hepatol201256495296422173168
   PubMed Web of Science ®Google Scholar
• KawanoYCohenDEMechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver diseaseJ Gastroenterol201348443444123397118
   PubMed Web of Science ®Google Scholar
• FuchsMNon-alcoholic fatty liver disease: the bile acid-activated farnesoid x receptor as an emerging treatment targetJ Lipids2012201293439622187656
   PubMedGoogle Scholar
• FerréPFoufelleFHepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1cDiabetes Obes Metab201012Suppl 2839221029304
   PubMed Web of Science ®Google Scholar
• MitsuyoshiHYasuiKHaranoYAnalysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver diseaseHepatol Res200939436637319054139
   PubMed Web of Science ®Google Scholar
• KohjimaMHiguchiNKatoMSREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver diseaseInt J Mol Med200821450751118360697
   PubMed Web of Science ®Google Scholar
• BaranowskiMBiological role of liver X receptorsJ Physiol Pharmacol200859Suppl 7315519258656
   PubMed Web of Science ®Google Scholar
• FauldsMHZhaoCDahlman-WrightKMolecular biology and functional genomics of liver X receptors (LXR) in relationship to metabolic diseasesCurr Opin Pharmacol201010669269720829110
   PubMed Web of Science ®Google Scholar
• LiangGYangJHortonJDHammerREGoldsteinJLBrownMSDiminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1cJ Biol Chem2002277119520952811782483
   PubMed Web of Science ®Google Scholar
• PeetDJTurleySDMaWCholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alphaCell19989356937049630215
   PubMed Web of Science ®Google Scholar
• RepaJJLiangGOuJRegulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbetaGenes Dev200014222819283011090130
   PubMed Web of Science ®Google Scholar
• SchultzJRTuHLukARole of LXRs in control of lipogenesisGenes Dev200014222831283811090131
   PubMed Web of Science ®Google Scholar
• HiguchiNKatoMShundoYLiver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver diseaseHepatol Res200838111122112918684130
   PubMed Web of Science ®Google Scholar
• Lima-CabelloEGarcia-MediavillaMVMiquilena-ColinaMEEnhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis CClin Sci (Lond)2011120623925020929443
   PubMed Web of Science ®Google Scholar
• HortonJDGoldsteinJLBrownMSCritical review SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liverJ Clin Invest200210991125113111994399
   PubMed Web of Science ®Google Scholar
• ShimomuraIShimanoHHortonJDGoldsteinJLBrownMSDifferential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cellsJ Clin Invest19979958388459062340
   PubMed Web of Science ®Google Scholar
• ShimomuraIBashmakovYIkemotoSHortonJDBrownMSGoldsteinJLInsulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetesProc Natl Acad Sci U S A19999624136561366110570128
   PubMed Web of Science ®Google Scholar
• ForetzMPacotCDugailIADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucoseMol Cell Biol19991953760376810207099
   PubMed Web of Science ®Google Scholar
• Azzout-MarnicheDBécardDGuichardCInsulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytesBiochem J2000350Pt 238939310947952
   PubMed Web of Science ®Google Scholar
• OsborneTFSterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin actionJ Biol Chem200027542323793238210934219
   PubMed Web of Science ®Google Scholar
• ChakravartyKLeahyPBecardDSterol regulatory element-binding protein-1c mimics the negative effect of insulin on phosphoenolpyruvate carboxykinase (GTP) gene transcriptionJ Biol Chem200127637348163482311443121
   PubMed Web of Science ®Google Scholar
• ShimanoHSterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genesProg Lipid Res200140643945211591434
   PubMed Web of Science ®Google Scholar
• HortonJDBashmakovYShimomuraIShimanoHRegulation of sterol regulatory element binding proteins in livers of fasted and refed miceProc Natl Acad Sci U S A19989511598759929600904
   PubMed Web of Science ®Google Scholar
• KimJBSarrafPWrightMNutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1J Clin Invest19981011199421459
   PubMed Web of Science ®Google Scholar
• NagayaTTanakaNSuzukiTDown-regulation of SREBP-1c is associated with the development of burned-out NASHJ Hepatol201053472473120655124
   PubMed Web of Science ®Google Scholar
• DenechaudPDDentinRGirardJPosticCRole of ChREBP in hepatic steatosis and insulin resistanceFEBS Lett20085821687317716660
   PubMed Web of Science ®Google Scholar
• FoufelleFFerréPNew perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1cBiochem J2002366Pt 237739112061893
   PubMed Web of Science ®Google Scholar
• DentinRPégorierJPBenhamedFHepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expressionJ Biol Chem200427919203142032614985368
   PubMed Web of Science ®Google Scholar
• IshiiSIizukaKMillerBCUyedaKCarbohydrate response element binding protein directly promotes lipogenic enzyme gene transcriptionProc Natl Acad Sci U S A200410144155971560215496471
   PubMed Web of Science ®Google Scholar
• MaLTsatsosNGTowleHCDirect role of ChREBP.Mlx in regulating hepatic glucose-responsive genesJ Biol Chem200528012120191202715664996
   PubMed Web of Science ®Google Scholar
• ChaJYRepaJJThe liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXRJ Biol Chem2007282174375117107947
   PubMed Web of Science ®Google Scholar
• UlvenSMDalenKTGustafssonJANebbHILXR is crucial in lipid metabolismProstaglandins Leukot Essent Fatty Acids2005731596315913974
   PubMed Web of Science ®Google Scholar
• ChenGLiangGOuJGoldsteinJLBrownMSCentral role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liverProc Natl Acad Sci U S A200410131112451125015266058
   PubMed Web of Science ®Google Scholar
• JosephSBLaffitteBPatelPHDirect and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptorsJ Biol Chem200227713110191102511790787
   PubMed Web of Science ®Google Scholar
• ZhangYYinLHillgartnerFBSREBP-1 integrates the actions of thyroid hormone, insulin, cAMP, and medium-chain fatty acids on ACCalpha transcription in hepatocytesJ Lipid Res200344235636812576518
   PubMed Web of Science ®Google Scholar
• ChuKMiyazakiMManWCNtambiJMStearoyl-coenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activationMol Cell Biol200626186786679816943421
   PubMed Web of Science ®Google Scholar
• MitroNMakPAVargasLThe nuclear receptor LXR is a glucose sensorNature2007445712421922317187055
   PubMed Web of Science ®Google Scholar
• ArdenCPetrieJLTudhopeSJElevated glucose represses liver glucokinase and induces its regulatory protein to safeguard hepatic phosphate homeostasisDiabetes201160123110312022013014
   PubMed Web of Science ®Google Scholar
• MaLRobinsonLNTowleHCChREBP*Mlx is the principal mediator of glucose-induced gene expression in the liverJ Biol Chem200628139287212873016885160
   PubMed Web of Science ®Google Scholar
• de la IglesiaNMukhtarMSeoaneJGuinovartJJAgiusLThe role of the regulatory protein of glucokinase in the glucose sensory mechanism of the hepatocyteJ Biol Chem200027514105971060310744755
   PubMed Web of Science ®Google Scholar
• IizukaKBruickRKLiangGHortonJDUyedaKDeficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysisProc Natl Acad Sci U S A2004101197281728615118080
   PubMed Web of Science ®Google Scholar
• IizukaKMillerBUyedaKDeficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) miceAm J Physiol Endocrinol Metab20062912E358E36416705063
   PubMed Web of Science ®Google Scholar
• DentinRBenhamedFHainaultILiver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob miceDiabetes20065582159217016873678
   PubMed Web of Science ®Google Scholar
• IizukaKTakedaJHorikawaYHepatic overexpression of dominant negative Mlx improves metabolic profile in diabetes-prone C57BL/6J miceBiochem Biophys Res Commun2009379249950419121288
   PubMed Web of Science ®Google Scholar
• BenhamedFDenechaudPLemoineMThe lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humansJ Clin Invest201212262176219422546860
   PubMed Web of Science ®Google Scholar
• BrownMSGoldsteinJLSelective versus total insulin resistance: a pathogenic paradoxCell Metab200872959618249166
   PubMed Web of Science ®Google Scholar
• FormanBMGoodeEChenJIdentification of a nuclear receptor that is activated by farnesol metabolitesCell19958156876937774010
   PubMed Web of Science ®Google Scholar
• LuTTMakishimaMRepaJJMolecular basis for feedback regulation of bile acid synthesis by nuclear receptorsMol Cell20006350751511030331
   PubMed Web of Science ®Google Scholar
• ZhangYKast-WoelbernHREdwardsPANatural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activationJ Biol Chem2003278110411012393883
   PubMed Web of Science ®Google Scholar
• DownesMVerdeciaMARoeckerAJA chemical, genetic, and structural analysis of the nuclear bile acid receptor FXRMol Cell20031141079109212718892
   PubMed Web of Science ®Google Scholar
• ThomasCPellicciariRPruzanskiMAuwerxJSchoonjansKTargeting bile-acid signalling for metabolic diseasesNat Rev Drug Discov20087867869318670431
   PubMed Web of Science ®Google Scholar
• KokTHulzebosCVWoltersHEnterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding proteinJ Biol Chem200327843419304193712917447
   PubMed Web of Science ®Google Scholar
• SinalCJTohkinMMiyataMWardJMLambertGGonzalezFJTargeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasisCell2000102673174411030617
   PubMed Web of Science ®Google Scholar
• WatanabeMHoutenSMWangLBile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1cJ Clin Invest2004113101408141815146238
   PubMed Web of Science ®Google Scholar
• MaKSahaPKChanLMooreDDFarnesoid X receptor is essential for normal glucose homeostasisJ Clin Invest200611641102110916557297
   PubMed Web of Science ®Google Scholar
• ZhangYLeeFYBarreraGActivation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic miceProc Natl Acad Sci U S A200610341006101116410358
   PubMed Web of Science ®Google Scholar
• YangZXShenWSunHEffects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver diseaseHepatol Int20104474174821286345
   PubMed Web of Science ®Google Scholar
• TeodoroJSRoloAPPalmeiraCMHepatic FXR: key regulator of whole-body energy metabolismTrends Endocrinol Metab2011221145846621862343
   PubMed Web of Science ®Google Scholar
• ModicaSGadaletaRMMoschettaADeciphering the nuclear bile acid receptor FXR paradigmNucl Recept Signal20108e00521383957
   PubMedGoogle Scholar
• DornCRienerMOKirovskiGExpression of fatty acid synthase in nonalcoholic fatty liver diseaseInt J Clin Exp Pathol20103550551420606731
   PubMed Web of Science ®Google Scholar
• KohjimaMEnjojiMHiguchiNRe-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver diseaseInt J Mol Med200720335135817671740
   PubMed Web of Science ®Google Scholar
• MorganKUyuniANandgiriGAltered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver diseaseEur J Gastroenterol Hepatol200820984385418794597
   PubMed Web of Science ®Google Scholar
• ZhangWPatilSChauhanBFoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expressionJ Biol Chem200628115101051011716492665
   PubMed Web of Science ®Google Scholar
• QuSAltomonteJPerdomoGAberrant Forkhead box O1 function is associated with impaired hepatic metabolismEndocrinology2006147125641565216997836
   PubMed Web of Science ®Google Scholar
• MatsumotoMHanSKitamuraTAcciliDDual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolismJ Clin Invest200611692464247216906224
   PubMed Web of Science ®Google Scholar
• ValentiLRamettaRDongiovanniPIncreased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitisDiabetes20085751355136218316359
   PubMed Web of Science ®Google Scholar
• SamuelVTChoiCSPhillipsTGTargeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin actionDiabetes20065572042205016804074
   PubMed Web of Science ®Google Scholar
• NakaeJBiggsWHKitamuraTRegulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1Nat Genet200232224525312219087
   PubMed Web of Science ®Google Scholar
• MandardSMüllerMKerstenSPeroxisome proliferator-activated receptor alpha target genesCell Mol Life Sci200461439341614999402
   PubMed Web of Science ®Google Scholar
• KerstenSSeydouxJPetersJMGonzalezFJDesvergneBWahliWPeroxisome proliferator-activated receptor alpha mediates the adaptive response to fastingJ Clin Invest1999103111489149810359558
   PubMed Web of Science ®Google Scholar
• HaranoYYasuiKToyamaTFenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liverLiver Int200626561362016762007
   PubMed Web of Science ®Google Scholar
• IpEFarrellGCRobertsonGHallPKirschRLeclercqICentral role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in miceHepatology200338112313212829994
   PubMed Web of Science ®Google Scholar
• ChouCJHaluzikMGregoryCWY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 miceJ Biol Chem200227727244842448911994294
   PubMed Web of Science ®Google Scholar
• HashimotoTCookWSQiCYeldandiAVReddyJKRaoMSDefect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fastingJ Biol Chem200027537289182892810844002
   PubMed Web of Science ®Google Scholar
• ReddyJKHashimotoTPeroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic systemAnnu Rev Nutr20012119323011375435
   PubMed Web of Science ®Google Scholar
• KashireddyPVRaoMSLack of peroxisome proliferator-activated receptor alpha in mice enhances methionine and choline deficient diet-induced steatohepatitisHepatol Res200430210411015519275
   PubMed Web of Science ®Google Scholar
• RaoMSPapreddyKMusunuriSOkonkwoAPrevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor alpha ligand in ratsIn Vivo200216214515212073774
   PubMed Web of Science ®Google Scholar
• IpEFarrellGHallPRobertsonGLeclercqIAdministration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in miceHepatology20043951286129615122757
   PubMed Web of Science ®Google Scholar
• TailleuxAWoutersKStaelsBRoles of PPARs in NAFLD: potential therapeutic targetsTriglyceride Metab Dis201218215809818
   Google Scholar
• Vanden BergheWVermeulenLDelerivePDe BosscherKStaelsBHaegemanGA paradigm for gene regulation: inflammation, NF-kappaB and PPARAdv Exp Med Biol200354418119614713228
   PubMed Web of Science ®Google Scholar
• DelerivePDe BosscherKBesnardSPeroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappa B and AP-1J Biol Chem199927445320483205410542237
   PubMed Web of Science ®Google Scholar
• DelerivePGervoisPFruchartJCStaelsBInduction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activatorsJ Biol Chem200027547367033670710980195
   PubMed Web of Science ®Google Scholar
• GervoisPVu-DacNKleemannRNegative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein betaJ Biol Chem200127636334713347711418615
   PubMed Web of Science ®Google Scholar
• GervoisPKleemannRPilonAGlobal suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrateJ Biol Chem200427916161541616014764586
   PubMed Web of Science ®Google Scholar
• HuangYYGusdonAMQuSNonalcoholic fatty liver disease: molecular pathways and therapeutic strategiesLipids Health Dis20131217124209497
   PubMed Web of Science ®Google Scholar
• TilgHMoschenARInflammatory mechanisms in the regulation of insulin resistanceMol Med2008143–422223118235842
   PubMed Web of Science ®Google Scholar
• TilgHAdipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosisCurr Pharm Des201016171893189520370678
   PubMed Web of Science ®Google Scholar
• MaedaNTakahashiMFunahashiTPPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived proteinDiabetes20015092094209911522676
   PubMed Web of Science ®Google Scholar
• WolfAMWolfDRumpoldHEnrichBTilgHAdiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytesBiochem Biophys Res Commun2004323263063515369797
   PubMed Web of Science ®Google Scholar
• TilgHMoschenARAdipocytokines: mediators linking adipose tissue, inflammation and immunityNat Rev Immunol200661077278316998510
   PubMed Web of Science ®Google Scholar
• XuAWangYKeshawHXuLYLamKSCooperGJThe fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in miceJ Clin Invest200311219110012840063
   PubMed Web of Science ®Google Scholar
• HuiJMHodgeAFarrellGCKenchJGKriketosAGeorgeJBeyond insulin resistance in NASH: TNF-alpha or adiponectin?Hepatology2004401465415239085
   PubMed Web of Science ®Google Scholar
• BaranovaAGowderSJSchlauchKGene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistanceObes Surg20061691118112516989692
   PubMed Web of Science ®Google Scholar
• KaserSMoschenACayonAAdiponectin and its receptors in non-alcoholic steatohepatitisGut200554111712115591515
   PubMed Web of Science ®Google Scholar
• MoschenARMolnarCWolfAMEffects of weight loss induced by bariatric surgery on hepatic adipocytokine expressionJ Hepatol200951476577719664840
   PubMed Web of Science ®Google Scholar
• MarraFBertolaniCAdipokines in liver diseasesHepatology200950395796919585655
   PubMed Web of Science ®Google Scholar
• HotamisligilGSShargillNSSpiegelmanBMAdipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistanceScience1993259509187917678183
   PubMed Web of Science ®Google Scholar
• KernPASaghizadehMOngJMBoschRJDeemRSimsoloRBThe expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipaseJ Clin Invest1995955211121197738178
   PubMed Web of Science ®Google Scholar
• MoschenARMolnarCGeigerSAnti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expressionGut20105991259126420660075
   PubMed Web of Science ®Google Scholar
• LangCHDobrescuCBagbyGJTumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose outputEndocrinology1992130143521727716
   PubMed Web of Science ®Google Scholar
• CrespoJCayónAFernández-GilPGene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patientsHepatology20013461158116311732005
   PubMed Web of Science ®Google Scholar
• LesmanaCRAHasanIBudihusodoUDiagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitisJ Dig Dis200910320120619659788
   PubMed Web of Science ®Google Scholar
• ValentiLFracanzaniALDongiovanniPTumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver diseaseGastroenterology2002122227428011832442
   PubMed Web of Science ®Google Scholar
• ZhouYJLiYYNieYQInfluence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese peopleJ Gastroenterol Hepatol201025477277720492333
   PubMed Web of Science ®Google Scholar
• GabayCKushnerIAcute-phase proteins and other systemic responses to inflammationN Engl J Med199934064484549971870
   PubMed Web of Science ®Google Scholar
• CressmanDEGreenbaumLEDeAngelisRALiver failure and defective hepatocyte regeneration in interleukin-6-deficient miceScience19962745291137913838910279
   PubMed Web of Science ®Google Scholar
• HaukelandJWDamåsJKKonopskiZSystemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2J Hepatol20064461167117416618517
   PubMed Web of Science ®Google Scholar
• SennJJKloverPJNowakIASuppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytesJ Biol Chem200327816137401374612560330
   PubMed Web of Science ®Google Scholar
• SamalBSunYStearnsGXieCSuggsSMcNieceICloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factorMol Cell Biol1994142143114378289818
   PubMed Web of Science ®Google Scholar
• MoschenARGernerRRTilgHPre-B Cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disordersCurr Pharm Des201016171913192020370672
   PubMed Web of Science ®Google Scholar
• AllerRde LuisDAIzaolaOInfluence of visfatin on histopathological changes of non-alcoholic fatty liver diseaseDig Dis Sci20095481772177719005759
   PubMed Web of Science ®Google Scholar
• JarrarMHBaranovaACollantesRAdipokines and cytokines in non-alcoholic fatty liver diseaseAliment Pharmacol Ther200827541242118081738
   PubMed Web of Science ®Google Scholar
• AuguetTTerraXPorrasJAPlasma visfatin levels and gene expression in morbidly obese women with associated fatty liver diseaseClin Biochem201346320220823174488
   PubMed Web of Science ®Google Scholar
• VidelaLAPettinelliPMisregulation of PPAR functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesityPPAR Res2012201210743423304111
   PubMed Web of Science ®Google Scholar
• OliverWRJrShenkJLSnaithMRA selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transportProc Natl Acad Sci U S A20019895306531111309497
   PubMed Web of Science ®Google Scholar
• LiuSHatanoBZhaoMRole of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulationJ Biol Chem201128621237124721059653
   PubMed Web of Science ®Google Scholar
• RisérusUSprecherDJohnsonTActivation of peroxisome proliferator-activated receptor (PPAR)delta Promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese menDiabetes200857233233918024853
   PubMed Web of Science ®Google Scholar
• OoiEMMWattsGFSprecherDLChanDCBarrettPHRMechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesityJ Clin Endocrinol Metab20119610E1568E157621816786
   PubMed Web of Science ®Google Scholar
• HaiderDGSchindlerKSchallerGPragerGWolztMLudvikBIncreased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric bandingJ Clin Endocrinol Metab20069141578158116449335
   PubMed Web of Science ®Google Scholar
• TackeFLueddeTTrautweinCInflammatory pathways in liver homeostasis and liver injuryClin Rev Allergy Immunol200936141218600481
   PubMed Web of Science ®Google Scholar
• Neuschwander-TetriBAHepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolitesHepatology201052277478820683968
   PubMed Web of Science ®Google Scholar
• FuSYangLLiPAberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesityNature2011473734852853121532591
   PubMed Web of Science ®Google Scholar
• RicchiMOdoardiMRCarulliLDifferential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytesJ Gastroenterol Hepatol200924583084019207680
   PubMed Web of Science ®Google Scholar
• HanMSParkSYShinzawaKLysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytesJ Lipid Res2008491849717951222
   PubMed Web of Science ®Google Scholar
• NolanCJLarterCZLipotoxicity: why do saturated fatty acids cause and monounsaturates protect against it?J Gastroenterol Hepatol200924570370619646010
   PubMed Web of Science ®Google Scholar
• Orellana-GavaldaJMHerreroLMalandrinoMIMolecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidationHepatology201153382183221319201
   PubMed Web of Science ®Google Scholar
• EndoMMasakiTSeikeMYoshimatsuHTNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c)Exp Biol Med (Maywood)2007232561462117463157
   PubMed Web of Science ®Google Scholar
• FeldsteinAEWieckowskaALopezARLiuYCZeinNNMcCulloughAJCytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation studyHepatology20095041072107819585618
   PubMed Web of Science ®Google Scholar
• FeldsteinAENovel insights into the pathophysiology of nonalcoholic fatty liver diseaseSemin Liver Dis201030439140120960378
   PubMed Web of Science ®Google Scholar
• AbdelmegeedMABanerjeeAYooSHCritical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitisJ Hepatol201257486086622668639
   PubMed Web of Science ®Google Scholar
• SethRKDasSKumarACYP2E1-dependent and leptin-mediated hepatic CD57 expression on CD8+ T cells aid progression of environment-linked nonalcoholic steatohepatitisToxicol Appl Pharmacol20142741425424211274
   PubMed Web of Science ®Google Scholar
• DasSSethRKKumarAPurinergic receptor X7 is a key modulator of metabolic oxidative stress-mediated autophagy and inflammation in experimental nonalcoholic steatohepatitisAm J Physiol Gastrointest Liver Physiol201330512G950G96324157968
   PubMed Web of Science ®Google Scholar
• Di MarzoVPiscitelliFMechoulamRCannabinoids and endocannabinoids in metabolic disorders with focus on diabetesHandb Exp Pharmacol20112037510421484568
   PubMedGoogle Scholar
• PacherPMechoulamRIs lipid signaling through cannabinoid 2 receptors part of a protective system?Prog Lipid Res201150219321121295074
   PubMed Web of Science ®Google Scholar
• PacherPBátkaiSKunosGThe endocannabinoid system as an emerging target of pharmacotherapyPharmacol Rev200658338946216968947
   PubMed Web of Science ®Google Scholar
• CotaDMarsicanoGTschapMThe endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesisJ Clin Invest2003112342343112897210
   PubMed Web of Science ®Google Scholar
• Osei-HyiamanDDePetrilloMPacherPEndocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesityJ Clin Invest200511551298130515864349
   PubMed Web of Science ®Google Scholar
• JeongWOsei-HyiamanDParkOParacrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liverCell Metab20087322723518316028
   PubMed Web of Science ®Google Scholar
• MallatATeixeira-ClercFDeveauxVManinSLotersztajnSThe endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openingsBr J Pharmacol201116371432144021457226
   PubMed Web of Science ®Google Scholar
• Osei-HyiamanDLiuJZhouLHepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in miceJ Clin Invest200811893160316918677409
   PubMed Web of Science ®Google Scholar
• TamJVemuriVKLiuJPeripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesityJ Clin Invest201012082953296620664173
   PubMed Web of Science ®Google Scholar
• Gary-BoboMElachouriGGallasJFRimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa ratsHepatology200746112212917526015
   PubMed Web of Science ®Google Scholar
• JourdanTDemizieuxLGrestiJAntagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explantsHepatology201255379079921987372
   PubMed Web of Science ®Google Scholar
• JourdanTDjaoutiLDemizieuxLGrestiJVergèsBDegracePCB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese miceDiabetes201059492693420110567
   PubMed Web of Science ®Google Scholar
• ChandaDKimDKLiTCannabinoid receptor type 1 (CB1R) signaling regulates hepatic gluconeogenesis via induction of endoplasmic reticulum-bound transcription factor cAMP-responsive element-binding protein H (CREBH) in primary hepatocytesJ Biol Chem201128632279712797921693703
   PubMed Web of Science ®Google Scholar
• HézodeCRoudot-ThoravalFNguyenSDaily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis CHepatology2005421637115892090
   PubMed Web of Science ®Google Scholar
• Muñoz-LuqueJRosJFernández-VaroGRegression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic ratsJ Pharmacol Exp Ther2008324247548318029545
   PubMed Web of Science ®Google Scholar
• Teixeira-ClercFJulienBGrenardPCB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosisNat Med200612667167616715087
   PubMed Web of Science ®Google Scholar
• Van GaalLPi-SunyerXDesprésJPMcCarthyCScheenAEfficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) programDiabetes Care200831Suppl 2S229S24018227491
   PubMed Web of Science ®Google Scholar